1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
DMK Pharmaceuticals Corporation

DMK Pharmaceuticals Corporation

DMKPQ
DMK Pharmaceuticals CorporationUS flagOther OTC
0.00
USD
- -
- -
1,010.00Market Cap
DMK Pharmaceuticals Corporation
DMKPQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
1,053.91
- -
- -
11.98
- -
- -
- -
- -
- -
25.89
32.28
27.02
29.06
2.51
1.07
2.22
0.92
Revenue per Share
3,831.94
-76.86
-61.18
-276.79
-130.22
-65.37
-85.96
-77.72
-71.56
-83.24
-63.06
-69.86
-36.16
-44.57
-22.25
-12.37
-5.64
Basic EPS, GAAP
-1,997.81
-77.27
-47.76
-82.68
-80.36
-44.5
-30.57
-159.89
-54.5
-85.12
-42.52
-64.82
-29.9
-19.49
-18.94
-12.42
-2.4
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-48,588.04
-4,968.42
-5,029.6
-779.19
-482.42
-409.26
-453.74
-439.58
-363.93
-353.81
-281.47
-274.01
-237.23
-207.47
-135.03
-142.26
-82.1
Book Value per Share
1,213.52
47.46
-34.74
-176.37
-25.74
-36.22
-51.71
24.55
8.16
-1.99
40.05
46.28
18.71
-3.3
12.57
-0.38
-1.34
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
2
4
Basic Weighted Avg Shares
3
- -
- -
- -
- -
- -
- -
- -
- -
6
13
15
22
3
2
5
4
Sales/Revenue/Turnover
-176.15
- -
- -
-1,371.51
- -
- -
- -
- -
- -
-389.32
-188.88
-261.51
-131.27
-1,140.96
-1,451.97
-526.88
-519.35
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
3
3
3
3
2
1
1
1
Depreciation Expense
10
-2
-2
-7
-7
-5
-7
-8
-14
-19
-26
-39
-28
-49
-46
-26
-22
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
363.59
- -
- -
-2,310.59
- -
- -
- -
- -
- -
-300.24
-195.35
-258.55
-124.41
-1,778.84
-2,074.91
-556.72
-614.21
Profit Margin (%)
3
2
- -
-5
-2
-3
-4
2
1
-2
13
14
4
-7
24
-2
-6
Working Capital
- -
1
1
- -
- -
- -
- -
- -
- -
3
3
- -
1
2
- -
- -
- -
LT Debt
3
1
-1
-4
-1
-3
-4
12
9
25
40
47
33
3
26
-1
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
10
Market Capitalization
2
1
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
8
3
8
Cash, Cash Equivalents & STI
3
1
7
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
13
15
13
Payables & Accruals
12
14
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.78%
87.25%
-103.12%
Free Cash Flow
69.73%
23.34%
-31.86%
Net Income, GAAP
25.41%
10.67%
-42.22%
Sales/Revenue/Turnover
- -
13.89%
115.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
1
1
1
-1
2
2022
1
- -
2
2
5
2023
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-8.32
-4.38
-5.81
- -
-22.25
2022
-4.84
-3.92
-2.05
- -
-12.37
2023
-4.09
-3.34
-0.2
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Global Hemp Group Inc. (GHG.CN)
Collegium Pharmaceutical, Inc. (COLL)
ARYx Therapeutics, Inc. (ARYX)
Northeast Pharmaceutical Group Co., Ltd. (000597.SZ)
BNC Korea Co., Ltd. (256840.KQ)
Guerbet S.A. (0ELV.L)
Business
DMK Pharmaceuticals Corporation (DMKPQ), a clinical-stage neuro-biotechnology company headquartered in San Diego, California, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases; its principal commercial products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions, including anaphylaxis from stinging and biting insects, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis, and ZIMHI naloxone injection for the treatment of opioid overdose; the company's lead clinical-stage product candidate is DPI-125, indicated for opioid use disorder, while Tempol remains in development for COVID-19 following a Phase 2/3 trial; founded in 2006 as Adamis Pharmaceuticals Corporation, it changed its name to DMK Pharmaceuticals Corporation in September 2023 after acquiring DMK Pharmaceuticals assets in February 2023; in June 2024, ZMI Management Inc. finalized the acquisition of ZIMHI assets, including patents, inventory, and manufacturing systems, with FFF Enterprises as sole distributor; the company filed for voluntary Chapter 11 reorganization on February 2, 2024, in the U.S. Bankruptcy Court for the District of Delaware, with a first amended joint liquidation plan approved on October 28, 2024, and it ceased operations as announced on November 14, 2024.